127 related articles for article (PubMed ID: 37357111)
1. Intraoperative paraaortic lymph node sampling during resection for pancreatic cancer: evolving role in the modern chemotherapy era.
Kazami Y; Oba A; Ono Y; Sato T; Inoue Y; Saiura A; Takahashi Y; Ito H
HPB (Oxford); 2023 Oct; 25(10):1169-1178. PubMed ID: 37357111
[TBL] [Abstract][Full Text] [Related]
2. Intraoperative frozen section analysis of para-aortic lymph nodes after neoadjuvant FOLFIRINOX: will it soon become useless?
Garnier J; Magallon C; Ewald J; Palen A; Marchese U; Delpero JR; Turrini O
Langenbecks Arch Surg; 2022 May; 407(3):1065-1071. PubMed ID: 34705107
[TBL] [Abstract][Full Text] [Related]
3. Survival equivalence in patients treated for borderline resectable and unresectable locally advanced pancreatic ductal adenocarcinoma: a systematic review and network meta-analysis.
Lindemann J; du Toit L; Kotze U; Bernon M; Krige J; Jonas E
HPB (Oxford); 2021 Feb; 23(2):173-186. PubMed ID: 33268268
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of paraaortic lymph node metastases in patients with ductal adenocarcinoma of the pancreatic head.
Petrova E; Mazzella E; Trojan J; Koch C; Schulze F; Bechstein WO; Schnitzbauer AA
Eur J Surg Oncol; 2023 May; 49(5):996-1000. PubMed ID: 36586788
[TBL] [Abstract][Full Text] [Related]
5. Significance of neoadjuvant therapy for borderline resectable pancreatic cancer: a multicenter retrospective study.
Kurahara H; Shinchi H; Ohtsuka T; Miyasaka Y; Matsunaga T; Noshiro H; Adachi T; Eguchi S; Imamura N; Nanashima A; Sakamoto K; Nagano H; Ohta M; Inomata M; Chikamoto A; Baba H; Watanabe Y; Nishihara K; Yasunaga M; Okuda K; Natsugoe S; Nakamura M
Langenbecks Arch Surg; 2019 Mar; 404(2):167-174. PubMed ID: 30649607
[TBL] [Abstract][Full Text] [Related]
6. Postoperative prognosis of pancreatic cancer with para-aortic lymph node metastasis: a multicenter study on 822 patients.
Sho M; Murakami Y; Motoi F; Satoi S; Matsumoto I; Kawai M; Honda G; Uemura K; Yanagimoto H; Kurata M; Fukumoto T; Akahori T; Kinoshita S; Nagai M; Nishiwada S; Unno M; Yamaue H; Nakajima Y
J Gastroenterol; 2015 Jun; 50(6):694-702. PubMed ID: 25341657
[TBL] [Abstract][Full Text] [Related]
7. Prognostic impact of para-aortic lymph node metastases in non-pancreatic periampullary cancer.
Hempel S; Oehme F; Müssle B; Aust DE; Distler M; Saeger HD; Weitz J; Welsch T
World J Surg Oncol; 2020 Jan; 18(1):16. PubMed ID: 31964383
[TBL] [Abstract][Full Text] [Related]
8. Pancreatic ductal adenocarcinoma and paraaortic lymph nodes metastases: The accuracy of intraoperative frozen section.
Doussot A; Bouvier A; Santucci N; Lequeu JB; Cheynel N; Ortega-Deballon P; Rat P; Facy O
Pancreatology; 2019 Jul; 19(5):710-715. PubMed ID: 31174978
[TBL] [Abstract][Full Text] [Related]
9. Prognostic Impact of Para-Aortic Lymph Node Micrometastasis in Pancreatic Ductal Adenocarcinoma.
Komo T; Murakami Y; Kondo N; Uemura K; Hashimoto Y; Nakagawa N; Urabe K; Takahashi S; Sueda T
Ann Surg Oncol; 2016 Jun; 23(6):2019-27. PubMed ID: 26856722
[TBL] [Abstract][Full Text] [Related]
10. Impact of para aortic lymph node removal on survival following resection for pancreatic adenocarcinoma.
Sillesen M; Hansen CP; Burgdorf SK; Dencker EE; Krohn PS; Gisela Kollbeck SL; Stender MT; Storkholm JH
BMC Surg; 2023 Aug; 23(1):214. PubMed ID: 37528360
[TBL] [Abstract][Full Text] [Related]
11. Intention to treat outcomes among patients with pancreatic cancer treated using International Study Group on Pancreatic Surgery recommended pathways for resectable and borderline resectable disease.
Kamarajah SK; Chatzizacharias N; Hodson J; Marcon F; Kalisvaart M; Punia P; Ting Ma Y; Dasari B; Marudanayagam R; Sutcliffe RP; Muiesan P; Mirza DF; Isaac J; Roberts KJ
ANZ J Surg; 2021 Jul; 91(7-8):1549-1557. PubMed ID: 33576568
[TBL] [Abstract][Full Text] [Related]
12. Meta-analysis comparing upfront surgery with neoadjuvant treatment in patients with resectable or borderline resectable pancreatic cancer.
Versteijne E; Vogel JA; Besselink MG; Busch ORC; Wilmink JW; Daams JG; van Eijck CHJ; Groot Koerkamp B; Rasch CRN; van Tienhoven G;
Br J Surg; 2018 Jul; 105(8):946-958. PubMed ID: 29708592
[TBL] [Abstract][Full Text] [Related]
13. Reassessment of the clinical significance of portal-superior mesenteric vein invasion in borderline resectable pancreatic cancer.
Hoshimoto S; Hishinuma S; Shirakawa H; Tomikawa M; Ozawa I; Wakamatsu S; Hoshi S; Hoshi N; Hirabayashi K; Ogata Y
Eur J Surg Oncol; 2017 Jun; 43(6):1068-1075. PubMed ID: 28427822
[TBL] [Abstract][Full Text] [Related]
14. Neoadjuvant therapy in borderline resectable pancreatic cancer: Outcomes in the era of changing practices and evolving evidence.
Chaudhari VA; Mitra A; Gupta V; Ostwal V; Ramaswamy A; Engineer R; Sirohi B; Shetty N; Bal M; DeSouza A; Bhandare MS; Shrikhande SV
Surgery; 2022 May; 171(5):1388-1395. PubMed ID: 34922745
[TBL] [Abstract][Full Text] [Related]
15. Neoadjuvant chemoradiation is associated with decreased lymph node ratio in borderline resectable pancreatic cancer: A propensity score matched analysis.
Peng JS; Morris-Stiff G; Ali NS; Wey J; Chalikonda S; El-Hayek KM; Walsh RM
Hepatobiliary Pancreat Dis Int; 2021 Feb; 20(1):74-79. PubMed ID: 32861576
[TBL] [Abstract][Full Text] [Related]
16. The experience of neoadjuvant chemotherapy versus upfront surgery in resectable pancreatic cancer: a cross sectional study.
Su YY; Chao YJ; Wang CJ; Liao TK; Su PJ; Huang CJ; Chiang NJ; Yu YT; Tsai HM; Chen LT; Shan YS
Int J Surg; 2023 Sep; 109(9):2614-2623. PubMed ID: 37300888
[TBL] [Abstract][Full Text] [Related]
17. Preoperative risk factors for para-aortic lymph node positivity in pancreatic cancer.
Okada K; Uemura K; Kondo N; Sumiyoshi T; Seo S; Otsuka H; Serikawa M; Ishii Y; Tsuboi T; Murakami Y; Takahashi S
Pancreatology; 2021 Apr; 21(3):606-612. PubMed ID: 33648880
[TBL] [Abstract][Full Text] [Related]
18. Oncologic Outcomes of Colon Cancer Patients with Extraregional Lymph Node Metastasis: Comparison of Isolated Paraaortic Lymph Node Metastasis with Resectable Liver Metastasis.
Bae SU; Han YD; Cho MS; Hur H; Min BS; Baik SH; Lee KY; Kim NK
Ann Surg Oncol; 2016 May; 23(5):1562-8. PubMed ID: 26714940
[TBL] [Abstract][Full Text] [Related]
19. Survival impact of distal pancreatectomy with en bloc celiac axis resection combined with neoadjuvant chemotherapy for borderline resectable or locally advanced pancreatic body carcinoma.
Murakami Y; Nakagawa N; Kondo N; Hashimoto Y; Okada K; Seo S; Otsuka H
Pancreatology; 2021 Apr; 21(3):564-572. PubMed ID: 33526385
[TBL] [Abstract][Full Text] [Related]
20. Survival in borderline resectable and locally advanced pancreatic cancer is determined by the duration and response of neoadjuvant therapy.
Wijetunga AR; Chua TC; Nahm CB; Pavlakis N; Clarke S; Chan DL; Diakos C; Maloney S; Ashrafi-Zadeh A; Kneebone A; Hruby G; Jamieson NB; Gill A; Mittal A; Samra JS
Eur J Surg Oncol; 2021 Oct; 47(10):2543-2550. PubMed ID: 33952409
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
